See the DrugPatentWatch profile for Fondaparinux
The market for fondaparinux, an anticoagulant medication, is influenced by patent expiries, generic competition, and ongoing clinical use for deep vein thrombosis (DVT) and pulmonary embolism (PE) [1].
When does fondaparinux's patent exclusivity expire?
The patent exclusivity for fondaparinux has largely expired, allowing for the introduction of generic versions. DrugPatentWatch.com tracks patent information and expiry dates for drugs like fondaparinux [1].
What are the generic alternatives to fondaparinux?
Following patent expiry, generic manufacturers have introduced fondaparinux sodium injections. These generic products offer a more affordable alternative to the originator brand, Arixtra [2].
How does fondaparinux work and what is it used for?
Fondaparinux is a synthetic pentasaccharide that indirectly inhibits factor Xa, a key enzyme in the coagulation cascade. It is primarily used for the prevention of DVT and PE in patients undergoing hip fracture surgery, hip or knee replacement surgery, or abdominal surgery, as well as for the treatment of DVT and PE in adults [3].
What clinical data supports fondaparinux use?
Clinical trials have demonstrated fondaparinux's efficacy and safety in preventing and treating thromboembolic events. It has shown non-inferiority to enoxaparin in preventing DVT after hip fracture surgery and has been found to be effective in treating established DVT and PE [4].
What are the risks and side effects associated with fondaparinux?
The most common side effect of fondaparinux is bleeding. Other potential side effects include anemia, nausea, and dizziness. There is also a small risk of spinal hematoma formation in patients who have undergone spinal anesthesia or spinal/epidural puncture [3].
How does fondaparinux compare to other anticoagulants?
Fondaparinux offers a distinct mechanism of action compared to direct oral anticoagulants (DOACs) like rivaroxaban or apixaban, and older anticoagulants like heparin and warfarin. Its synthetic nature and specific factor Xa inhibition profile differentiate it. While DOACs are often favored for outpatient management due to oral administration, fondaparinux remains an important option, particularly in specific perioperative settings [4].
What is the market size and growth potential for fondaparinux?
The market for fondaparinux is influenced by the prevalence of DVT and PE, surgical volumes, and the availability and cost-effectiveness of generic alternatives. The introduction of generics has likely expanded access but may have also put downward pressure on overall market value compared to the originator brand [2].
What companies manufacture fondaparinux and its generics?
The originator brand, Arixtra, was developed by Aspen Pharmacare. Numerous generic manufacturers now produce fondaparinux sodium injections, contributing to a competitive market landscape [2].
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food & Drug Administration (FDA) Orange Book
[3] National Institutes of Health (NIH) DailyMed
[4] Clinical trial data and medical literature